$50 million is enough to avoid any capital raisings and fund the pipeline, but not as much as I'd hoped for. With this structure, a lot is dependent on the commercialisation success of Axiron - as Evamist shows, products don't always live up to their promise.
I'm happy to hold now. To push the market cap up over $500m, though, I think we'll need to see either approval and sales traction for Axiron or signs of progress with the rest of the pipeline.
ACR Price at posting:
$2.40 Sentiment: LT Buy Disclosure: Held
